PRESS RELEASE published on 04/09/2026 at 15:38, 3 months 19 days ago Form 8.3 - The Vanguard Group, Inc.: Beazley plc The Vanguard Group, Inc. discloses 5.03% stake in Beazley plc through Form 8.3 on 09-Apr-2026 Form 8.3 Disclosure Vanguard Group Stake Beazley Plc
PRESS RELEASE published on 04/09/2026 at 15:37, 3 months 19 days ago Form 8.3 - The Vanguard Group, Inc.: Bluefield Solar Income Fund Limited The Vanguard Group, Inc. files Form 8.3 relating to Bluefield Solar Income Fund Limited disclosing a 1.23% interest in relevant securities on 08 April 2026 Securities Form 8.3 Disclosure Vanguard Group Bluefield Solar Income Fund
PRESS RELEASE published on 04/09/2026 at 15:37, 3 months 19 days ago Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital Pierre et Vacances provides regulated information regarding total number of shares and voting rights as of 31 March 2026 Voting Rights Shares Regulated Information French Autorité Des Marchés Financiers Pierre Et Vacances
PRESS RELEASE published on 04/09/2026 at 15:36, 3 months 19 days ago Form 8.3 - The Vanguard Group, Inc.: Picton Property Income Limited The Vanguard Group, Inc. discloses 5.05% interest in Picton Property Income Limited. Form 8.3 filing under Rule 8.3 of the Takeover Code Form 8.3 Disclosure Takeover Code Vanguard Group Picton Property Income Limited
PRESS RELEASE published on 04/09/2026 at 15:36, 3 months 19 days ago Form 8.3 - The Vanguard Group, Inc.: Senior plc The Vanguard Group, Inc. discloses a 5.14% stake in Senior plc as of 08 April 2026. Details on holding disclosed in Form 8.3 Form 8.3 Vanguard Group Financial Disclosure Stake Disclosure Senior Plc
PRESS RELEASE published on 04/09/2026 at 15:35, 3 months 19 days ago Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc The Vanguard Group, Inc. discloses a 3.60% interest in Spire Healthcare Group plc's 1p ordinary shares. Position disclosed on 08 April 2026. Dealing disclosure includes sale of securities Disclosure The Vanguard Group Sale Interest Spire Healthcare Group Plc
PRESS RELEASE published on 04/09/2026 at 15:34, 3 months 19 days ago Form 8.3 - The Vanguard Group, Inc.: Life Science REIT plc The Vanguard Group, Inc. discloses a 0.94% interest in Life Science REIT plc through Form 8.3. Details of securities holdings and dealings provided Securities Form 8.3 Disclosure The Vanguard Group Life Science REIT Plc
PRESS RELEASE published on 04/09/2026 at 15:34, 3 months 19 days ago Form 8.3 - The Vanguard Group, Inc.: NCC Group plc The Vanguard Group, Inc. discloses a 5.09% stake in NCC Group plc through Form 8.3 on 09-Apr-2026 Form 8.3 The Vanguard Group Financial Disclosure Stake Disclosure NCC Group Plc
PRESS RELEASE published on 04/09/2026 at 15:33, 3 months 19 days ago Form 8.3 - The Vanguard Group, Inc.: International Personal Finance plc The Vanguard Group, Inc. discloses a 1.33% ownership in International Personal Finance plc as of 08 April 2026. Details of share sale provided Vanguard Group Inc. Ownership Disclosure Financial Disclosure Share Sale International Personal Finance Plc
PRESS RELEASE published on 04/09/2026 at 15:33, 3 months 19 days ago Form 8.3 - The Vanguard Group, Inc.: JTC plc The Vanguard Group, Inc. discloses a 5.09% stake in JTC plc. Details of securities and dealings in compliance with Rule 8.3 of the Takeover Code Securities The Vanguard Group, Inc. Disclosure Rule 8.3 JTC Plc
Published on 07/28/2026 at 15:00, 40 minutes ago Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog
Published on 07/28/2026 at 14:45, 55 minutes ago Trifecta Gold Introduces the Liam and Lois Projects, East-Central Yukon and Grants Stock Options
Published on 07/28/2026 at 14:30, 1 hour 10 minutes ago Sekur Private Data Reports 25% Month-Over-Month Increase in Average Revenue Per User as Premium Pivot Takes Hold
Published on 07/28/2026 at 14:30, 1 hour 10 minutes ago NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial
Published on 07/28/2026 at 14:00, 1 hour 40 minutes ago Adcore Delivers Five Autonomous AI Agents, Exceeding Its Public Q2 Roadmap Commitment
Published on 07/28/2026 at 15:20, 20 minutes ago Tines Launches 3B to Help Enterprises Govern AI Workflows, Apps and Agents
Published on 07/28/2026 at 14:49, 51 minutes ago Bell Ringing Ceremony in Frankfurt: HELIOS SOLAR AG Celebrates Successful Stock Market Debut
Published on 07/28/2026 at 14:47, 53 minutes ago EQS-Adhoc: HELIOS SOLAR AG Places a Further Four Million Shares in a Private Placement with Institutional Investor in Asia
Published on 07/28/2026 at 14:05, 1 hour 35 minutes ago Claros Technologies Raises $55 Million Series B Financing to Accelerate Global Commercialization of PFAS Destruction Technology
Published on 07/27/2026 at 18:00, 21 hours 40 minutes ago Saint-Gobain accelerates in Asia with two targeted acquisitions
